Certara Introduces Simcyp Biopharmaceutics Software To Increase Efficiency Of Novel And Generic Drug Formulation & Development
Portfolio Pulse from Benzinga Newsdesk
Certara, Inc. (NASDAQ:CERT) has launched Simcyp Biopharmaceutics software, a new addition to its Simcyp Simulator biosimulation platform. This software aids biopharmaceutic, formulation, and CMC scientists in efficiently formulating both novel and generic small molecule medicines. It offers capabilities such as virtual bioequivalence studies to replace costly clinical trials, optimization of formulations for complex drugs, and informing drug labels with PBPK models. The software is recognized for supporting label claims for over 100 approved therapies and is available as a standalone product.
November 21, 2023 | 9:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Certara has introduced Simcyp Biopharmaceutics software, enhancing its biosimulation platform and potentially increasing its service offerings to clients in drug development. This could lead to increased adoption and revenue growth.
The introduction of Simcyp Biopharmaceutics software is directly related to Certara's core business of biosimulation. The software's ability to aid in drug formulation and potentially replace costly clinical trials with virtual studies is likely to be seen as a positive development by investors. This could lead to increased adoption of the software by clients, which in turn may result in revenue growth for Certara in the short term. The confidence in this analysis is high due to the clear connection between the product launch and Certara's business operations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100